Windlas Biotech Limited has informed the Exchange about Transcript

Windlas Biotech reported strong FY26 performance with revenue of INR904 crores (up 19% Y-o-Y) and Q4 revenue of INR238 crores (up 18%). The company achieved 13 consecutive quarters of record revenue with adjusted EBITDA of INR121 crores (13.4%) and PAT of INR83 crores (9.2%). Management highlighted FY26 as a defining year, crossing INR900 crores for the first time, with highest post-listing EPS of INR31.60 and ROCE/ROE above 25%. The CDMO vertical contributed 73% of revenue growing 20% Y-o-Y, while exports surged 40% to INR46 crores. Plant 6 is on track for H1 FY27 commercialization. Management maintained customer diversification (top customer at 6.5%, top 10 at 32%) and discussed capacity expansion plans for FY28 when utilization reaches 60%.